The Effect of γ-Guanidinobutyric Acid on the Clotting Time of Normal Plasma and on the Euglobulin Lysis Time of Fibrinolytically Active Plasma by Fisher, Lyman M. et al.
The Effect of ')"-Guanidinobutyric Acid on 
the Clotting Time of Normal Plasma 
and on the Euglobulin Lysis Time 
of Fibrinolytica lly Active Plasma* 
LYMAN M. FISHER, PHYLLIS S. ROBERTS, AND WARNER E. BRAXTON 
Division of Clinical Pathology, Department of Pathology, and Department of 
Medicine, Medical College of Virginia, Richmond 
It has been established that e-amino-
caproic acid (EACA) inhibits the ac-
tivation of human plasminogen 
(Ablondi et al., 1959; Alkjaersig, 
Fletcher, and Sherry, 1959). Because 
of this observation, this compound has 
been used extensively to inhibit the 
pathologically occurring fibrinolytic 
system in patients. Recently Roberts 
(1965) reported that another com-
pound, y-guanidinobutyric acid 
(GGBA), like EACA, inhibits the 
Iysis of human blood clots. Further-
more, GGBA, unlike EACA, retards 
the formation of these clots. 
The present investigation was un-
dertaken to determine whether GGBA 
inhibits clot formation in the one-
stage prothrombin and in the partial 
thromboplastin time tests. In addition, 
the ability of GGBA to inhibit clot 
lysis was tested using blood from a 
patient showing active fibrinolysis. 
Materials and Methods 
Blood was collected in a 3.8% so-
dium citrate anticoagulant (9 parts 
blood, 1 part citrate) from 15 indi-
viduals. The blood was centrifuged at 
2,500 rpm in an angle centrifuge for 
10 minutes to obtain the plasma. Clot-
ting tests were performed in duplicate 
in glass test tubes (10 X 75 mm. at 
37° C. Solutions of EACA (Mann Re-
search Laboratories, New York, N.Y.) 
and GGBA (Calbiochem, Los Angeles, 
Calif.) were prepared, each having a 
concentration of 0.1 M in physiologi-
cal saline. The pH of the EACA solu-
tion was 7.02 and that of the GGBA 
solution was 7.03. 
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The clotting tests were performed 
in the following manner. 
1. One-stage prothrombin time: 0.1 
ml of plasma; 0.1 ml of either physio-
logical saline (control), 0.1 M EACA, 
or 0.1 M GGBA; 0.2 ml of equal 
volumes of thromboplastin and CaCl2 
(0.025 M). The time taken for clot 
formation was measured. 
2. Partial thromboplastin time: 0.1 
ml of plasma; 0.1 ml of either physio-
logical saline (control), 0.1 M EACA, 
or 0.1 M GGBA; 0.1 ml of Thrombo-
fax (Ortho Research Foundation, Rari-
tan, N.J.). The mixture was incubated 
for 30 seconds, and then 0.1 ml of 
CaCI2 (0.025 M) was added. The tubes 
were removed from the water bath af-
ter incubation for 60 seconds, wiped 
dry, tilted, and the time taken for clot 
formation was measured. 
The euglobulin lysis time was per-
formed as outlined by von Kaulla and 
Schultz (1958), except that 0.1 ml of 
either physiological saline, 0.1 M 
EACA, or 0.1 M GGBA was added 
to the euglobulin precipitate. 
Results and Discussion 
The effects of EACA and GGBA 
on the clotting systems are shown in 
table 1. 
There was no significant difference 
between the values obtained with the 
one-stage test for the samples contain-
ing saline or EACA. The values ob-
tained when GGBA was added, how-
ever, were significantly prolonged (p 
< 0.001) when compared with the saline 
control. 
The findings for the partial throm-
boplastin test were similar to those 
obtained for the one-stage test. GGBA 
significantly prolonged the clotting 
time when compared with the samples 
containing either saline or EACA (p 
< 0.01). 
Opportunity to test the usefulness 
of GGBA in a clinical situation pre-
sented itself when a 23-year-old Ne-
gro female, gravida 5 , para 3, abortus 
1, delivered unattended at home a 
stillborn term infant. Vaginal bleeding 
was profuse, and a physician was 
called. When the latter noted that the 
blood failed to clot, the patient was 
transferred to the Medical College of 
Virginia Hospital, arriving in a state 
of shock. Numerous blood samples 
were drawn and the clots lysed spon-
taneously within J;2 hour even though 
considerable fresh blood and fibrino-
gen were administered. Following the 
demonstration of a lytic process, 
BACA was given intravenously and 
an almost immediate cessation of the 
lysis occurred. The results of euglob-
ulin lysis times performed on the 
plasma samples obtained prior to and 
after the administration of BACA 
(table 2) show that GGBA was effec-
tive in inhibiting lysis, but to a lesser 
·.degree than was BACA. 
GGBA is a naturally occurring 
compound (Pisano, Abraham, and 
Udenfriend, 1963) of low toxicity 
(Kamiya, Kiyota, and Kita, 1962). 
We have shown here that it, like 
BACA, can inhibit the lysis of a clot 
made from the plasma of a patient 
with pathological fibrinolytic activity. 
Therefore, it appears that GGBA, like 
BACA, interferes with the activation 
of human plasminogen by the natu-
rally occurring activator. This work 
also confirms that GGBA inhibits the 
formation of clots when it is added to 
normal plasma in the one-stage pro-
thrombin or the partial thromboplas-
tin time tests, while BACA has no 
effect. 
The mechanism of action of GGBA 
in the formation and lysis of blood 
clots is unknown. 
TABLE 1 
Effect EACA and GGBA on the One-Stage Prothrombin and Partial 
Thromboplastin Times 
No. of Samples 
Saline control . .... . . .. 15 
EACA, 0 .1 M . ... . . .. . . 15 
GGBA, 0 .1 M . 15 
* S.D. standard deviation . 
Summary 
The addition of y-guanidinobutyric 
acid (GGBA) to human plasma sig-
nificantly prolonged the one-stage pro-
thrombin and the partial thrombo-
plastin times. On the other hand, the 
addition of e-aminocaproic acid 
(BACA) had no significant effect on 
either of these tests. GGBA inhibited 
the lysis of a clot that was formed 
from the euglobulin fraction of the 
blood of an obstetrical patient with 
active fibrinolysis. BACA inhibited the 
lysis to a lesser degree. 
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